RANDOMIZED, OPEN, MULTICENTER, PROSPECTIVE, PHASE II CLINICAL TRIAL OF DOXORUBICIN vs. TRABECTEDIN PLUS DOXORUBICIN IN THE FIRST LINE TREATMENT OF PATIENTS WITH ADVANCED NON OPERABLE AND/OR METASTATIC SOFT TISSUE SARCOMAS.

Trial Profile

RANDOMIZED, OPEN, MULTICENTER, PROSPECTIVE, PHASE II CLINICAL TRIAL OF DOXORUBICIN vs. TRABECTEDIN PLUS DOXORUBICIN IN THE FIRST LINE TREATMENT OF PATIENTS WITH ADVANCED NON OPERABLE AND/OR METASTATIC SOFT TISSUE SARCOMAS.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 22 Jul 2017

At a glance

  • Drugs Trabectedin (Primary) ; Doxorubicin
  • Indications Haemangiosarcoma; Leiomyosarcoma; Liposarcoma; Soft tissue sarcoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Jun 2017 Results (n=198) assessing role of FAS for trabectadin in second lines of advanced soft tissue sarcoma presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 16 May 2016 Primary endpoint has not been met. (Progression free survival), as per an article published in the Journal of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top